Thermo Fisher Scientific at ESMO 2017 Congress

Dr Normanno, MD, earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in medical oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumour Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Chief of the Cell Biology and Biotherapy Unit at the same hospital, and since 2006 also Director of the Research Department. Since 1993 Dr Normanno’s area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumours; the use of antisense oligonucleotides and inhibitors of receptors in experimental models of molecular therapy of carcinomas; identification of markers of response or resistance to anti-EGFR agents. Dr Normanno is the author of over 140 papers published in peer reviewed journals with an H Index of 46.

José Carlos Machado (JCM) vice-president of the Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), where he is also Department Chair. He is Associate Professor in the Faculty of Medicine of Porto. His research interest stands in the area of molecular genetics of cancer, and cancer immunology. He is internationally best known for his research in the area of helicobacter pylori-related gastric carcinoma. The scientific question that drives his research group is how is genetic information transferred between cancer cells, and how does that transference impact on the heterogeneity, diversity and plasticity of cancer cells. He has have been awarded research projects by the Portuguese Foundation for Science and Technology, by the Portuguese Agency for Innovation, by the Portuguese Ministry of Health, by the European Union, and several other funding agencies. He is also the coordinator of the Molecular Pathology laboratory of Ipatimup. This laboratory is one of the reference laboratories in Portugal for the detection of clinically actionable cancer-associated mutations. It is also one of the reference labs for the genetic diagnosis of hereditary cancer syndromes.

Prof. Isabelle Soubeyran is Head of the Molecular Pathology Unit, Department of Pathology of Institut Bergonié in Bordeaux. She has received her MD diploma and specialised in anatomical pathology at University Bordeaux Segalen and did her phD on Integrated Systems, Environment and Biodiversity at Ecole Pratique des Hautes Etudes college in Paris. She is member of many international scientific organisations and is publishing in high value scientific journals including J Mol Diagn, J Clin Oncol, Leukemia, Oncogene and others.